AERI · Aerie Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.13M | $33.31M | $29.84M | - | $29.31M | $27.18M | $22.97M | - | $20.08M | $18.03M |
| Cost of Revenue | $6.93M | $3.74M | $6.78M | - | $7.90M | $6.18M | $6.70M | - | $5.38M | $7.33M |
| Gross Profit | $29.20M | $29.57M | $23.05M | - | $21.41M | $21.01M | $16.27M | - | $14.70M | $10.71M |
| R&D | $21.99M | $19.56M | $25.17M | - | $19.13M | $17.97M | $17.89M | - | $16.16M | $19.94M |
| SG&A | $33.88M | $28.15M | $31.52M | - | $34.66M | $34.54M | $32.60M | - | $32.03M | $33.24M |
| Total Operating Expenses | $62.80M | $51.45M | $63.48M | - | $61.69M | $58.69M | $57.19M | - | $53.69M | $60.59M |
| D&A | - | - | $1.60M | - | - | - | $1.50M | - | - | - |
| Operating Income | ($26.67M) | ($18.14M) | ($33.64M) | - | ($32.37M) | ($31.50M) | ($34.22M) | - | ($33.60M) | ($42.55M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $95.0K | $48.0K | $693.0K | - | $58.0K | $18.0K | $31.0K | - | $0 | $0 |
| Net Income | ($26.83M) | ($19.37M) | ($35.89M) | - | ($39.69M) | ($38.69M) | ($41.96M) | - | ($39.65M) | ($48.19M) |
| EPS - Basic | ($0.56) | ($0.41) | ($0.91) | - | ($0.86) | ($1.05) | - | - | - | - |
| EPS - Diluted | ($0.56) | ($0.41) | ($0.76) | - | ($0.86) | ($1.05) | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.09M | $39.44M | $56.44M | $37.19M | $61.85M | $79.96M | $122.69M | $151.57M | $129.79M | $151.30M |
| Accounts Receivable | $73.88M | $68.08M | $63.62M | $68.83M | $64.57M | $59.15M | $46.15M | $56.02M | $46.85M | $43.08M |
| Inventory | $46.76M | $47.01M | $40.19M | $40.41M | $30.05M | $30.70M | $28.32M | $27.06M | $20.84M | $19.09M |
| Accounts Payable | $9.06M | $9.28M | $7.88M | $8.29M | $8.08M | $7.44M | $6.52M | $8.83M | $4.54M | $6.66M |
| Current Assets | $302.81M | $311.41M | $316.97M | $355.65M | $275.95M | $289.02M | $293.58M | $331.75M | $295.21M | $313.08M |
| Total Assets | $375.59M | $385.34M | $395.55M | $431.39M | $351.80M | $355.53M | $362.73M | $402.05M | $366.69M | $385.25M |
| Current Liabilities | $133.33M | $119.66M | $115.29M | $124.99M | $118.13M | $108.09M | $93.36M | $104.47M | $88.64M | $83.86M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $539.57M | $526.47M | $521.26M | $448.72M | $424.68M | $395.14M | $373.10M | $378.08M | $306.59M | $295.44M |
| Stockholders' Equity | ($163.98M) | ($141.13M) | ($125.71M) | ($17.33M) | ($72.88M) | ($39.61M) | ($10.37M) | $23.97M | $60.10M | $89.81M |
| Retained Earnings | ($1.19B) | ($1.16B) | ($1.14B) | ($1.15B) | ($1.20B) | ($1.16B) | ($1.12B) | ($1.08B) | ($1.03B) | ($993.32M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $61.91M | - | - | - | ($30.05M) | - | - | - |
| Investing Cash Flow | - | - | ($42.30M) | - | - | - | $2.28M | - | - | - |
| Financing Cash Flow | - | - | ($357.0K) | - | - | - | ($1.10M) | - | - | - |
| CapEx | - | - | $1.60M | - | - | - | $772.0K | - | - | - |
| Free Cash Flow | - | - | $60.31M | - | - | - | ($30.83M) | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 80.8% | 88.8% | 77.3% | - | 73.1% | 77.3% | 70.8% | - | 73.2% | 59.4% |
| Operating margin | -73.8% | -54.4% | -112.8% | - | -110.4% | -115.9% | -149.0% | - | -167.3% | -236.0% |
| EBITDA margin | - | - | -107.4% | - | - | - | -142.4% | - | - | - |
| Net margin | -74.3% | -58.2% | -120.3% | - | -135.4% | -142.3% | -182.7% | - | -197.4% | -267.2% |
| Free cash flow margin | - | - | 202.2% | - | - | - | -134.2% | - | - | - |
| FCF / Net income | - | - | -1.68 | - | - | - | 0.73 | - | - | - |
| R&D / Revenue | 60.9% | 58.7% | 84.4% | - | 65.3% | 66.1% | 77.9% | - | 80.5% | 110.6% |
| SG&A / Revenue | 93.8% | 84.5% | 105.7% | - | 118.2% | 127.1% | 141.9% | - | 159.5% | 184.3% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.1% | -5.0% | -9.1% | - | -11.3% | -10.9% | -11.6% | - | -10.8% | -12.5% |
| Return on equity | 16.4% | 13.7% | 28.6% | - | 54.5% | 97.7% | 404.7% | - | -66.0% | -53.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.27 | 2.60 | 2.75 | 2.85 | 2.34 | 2.67 | 3.14 | 3.18 | 3.33 | 3.73 |
| Quick ratio | 1.92 | 2.21 | 2.40 | 2.52 | 2.08 | 2.39 | 2.84 | 2.92 | 3.10 | 3.51 |
| Cash ratio | 0.41 | 0.33 | 0.49 | 0.30 | 0.52 | 0.74 | 1.31 | 1.45 | 1.46 | 1.80 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -2.29 | -2.73 | -3.15 | -24.89 | -4.83 | -8.97 | -34.99 | 16.77 | 6.10 | 4.29 |
| Liabilities / Assets | 1.44 | 1.37 | 1.32 | 1.04 | 1.21 | 1.11 | 1.03 | 0.94 | 0.84 | 0.77 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | 0.09 | 0.08 | - | 0.08 | 0.08 | 0.06 | - | 0.05 | 0.05 |
| Inventory turnover | 0.15 | 0.08 | 0.17 | - | 0.26 | 0.20 | 0.24 | - | 0.26 | 0.38 |
| Days sales outstanding | 746d | 746d | 778d | - | 804d | 794d | 733d | - | 852d | 872d |
| Days inventory outstanding | 2463d | 4586d | 2164d | - | 1389d | 1814d | 1543d | - | 1414d | 951d |
| Days payable outstanding | 477d | 905d | 424d | - | 373d | 439d | 355d | - | 308d | 332d |
| Cash conversion cycle | 2732d | 4427d | 2518d | - | 1820d | 2169d | 1921d | - | 1958d | 1491d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 23.3% | 22.5% | 29.9% | - | 46.0% | 50.8% | 12.9% | - | 8.3% | 13.9% |
| Revenue CAGR (3y) | 24.9% | 28.1% | 40.1% | - | - | 123.9% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 36.4% | 40.8% | 41.7% | - | 45.7% | 96.2% | 14.2% | - | -10.8% | -29.2% |
| Operating income growth (YoY) | 17.6% | 42.4% | 1.7% | - | 3.7% | 26.0% | 22.1% | - | 22.4% | 7.6% |
| Net income growth (YoY) | 32.4% | 49.9% | 14.5% | - | -0.1% | 19.7% | 14.6% | - | 19.7% | -2.2% |
| EPS growth (YoY) | 34.9% | 61.0% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | 28.4% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -125.0% | -256.3% | -1112.5% | - | - | - | - | -85.6% | -71.3% | -42.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$194.13M totalProduct$112.13M · 57.8%
License$82.00M · 42.2%
Geographic
$80.00M totalEurope$80.00M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing AERIE PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.